Literature DB >> 2674692

Insulin, insulin-like growth factor I and platelet-derived growth factor interact additively in the induction of the protooncogene c-myc and cellular proliferation in cultured bovine aortic smooth muscle cells.

N K Banskota1, R Taub, K Zellner, G L King.   

Abstract

Vascular smooth muscle cell (SMC) growth is under the influence of various growth factors. We demonstrate that platelet-derived growth factor (PDGF) stimulates DNA synthesis of cultured bovine aortic SMCs by 2.5- to 3.5-fold. PDGF also exhibits additivity with insulin and insulin-like growth factor I (IGF-I) for DNA synthesis and cellular proliferation. Insulin (2 x 10(-6) M), IGF-I (1 x 10(-8) M), and PDGF (1 x 10(-9) M) cause a 60-80% increase in cell numbers over basal, but PDGF with insulin or IGF causes a 40-150% increase over basal. No additivity between insulin and IGF-I is evident. PDGF also induces commitment to DNA synthesis earlier than insulin or IGF-I. After exposure to PDGF for 4 h, SMCs incorporate 3H-thymidine to 60% of maximum (with PDGF alone) levels (achieved after exposure of 12 h or longer). Insulin and IGF-I exposure for 4 h, on the other hand, achieves 3H-thymidine incorporation that is only a 20-30% of maximum (with insulin or IGF-I alone). Insulin, IGF-I, and PDGF increase mRNA levels of the protooncogene c-myc. This induction begins within 30 min of exposure to these growth factors which causes a 4- to 6-fold increase in c-myc mRNA levels. Additivity is also observed between PDGF with insulin or IGF-I, but not between insulin or IGF-I, in c-myc induction. C-myc mRNA levels remain elevated as long as the hormones are present, although there's a tendency for the mRNA levels to fall off with insulin and IGF-I.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674692     DOI: 10.1210/mend-3-8-1183

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  19 in total

1.  Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats.

Authors:  Z Y Jiang; Y W Lin; A Clemont; E P Feener; K D Hein; M Igarashi; T Yamauchi; M F White; G L King
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

2.  Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice.

Authors:  Christian Rask-Madsen; Erica Buonomo; Qian Li; Kyoungmin Park; Allen C Clermont; Oluwatobi Yerokun; Mark Rekhter; George L King
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-15       Impact factor: 8.311

3.  Platelet-derived growth factor activates phospholipase D and chemotactic responses in vascular smooth muscle cells.

Authors:  C J Welsh; K Schmeichel; K McBride
Journal:  In Vitro Cell Dev Biol       Date:  1991-05

Review 4.  Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering.

Authors:  Jeffrey A Beamish; Ping He; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part B Rev       Date:  2010-10       Impact factor: 6.389

5.  Heparin-like glycosaminoglycans influence growth and phenotype of human arterial smooth muscle cells in vitro. I. Evidence for reversible binding and inactivation of the platelet-derived growth factor by heparin.

Authors:  G Fager; G Camejo; G Bondjers
Journal:  In Vitro Cell Dev Biol       Date:  1992-03

6.  Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

Authors:  R E Law; W P Meehan; X P Xi; K Graf; D A Wuthrich; W Coats; D Faxon; W A Hsueh
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

Review 7.  Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry.

Authors:  R Ross
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

8.  Insulin enhances angiotensin II induced DNA synthesis in vascular smooth muscle cells of the rat.

Authors:  Y Ko; A Sachinidis; A J Wieczorek; M Appenheimer; R Düsing; H Vetter
Journal:  Clin Investig       Date:  1993-05

Review 9.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone.

Authors:  H Kiaris; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.